Trial Profile
A Phase 1/2 Study of Edasalonexent (CAT-1004) in Pediatric Patients With Duchenne Muscular Dystrophy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Sep 2022
Price :
$35
*
At a glance
- Drugs Edasalonexent (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms MoveDMD
- Sponsors Astria Therapeutics; Catabasis Pharmaceuticals
- 28 Sep 2020 Results presented in a Catabasis Pharmaceuticals media release.
- 28 Sep 2020 According to a Catabasis Pharmaceuticals media release, long-term safety results from this trial and open-label extension were presented at the Virtual 25th International Congress of the World Muscle Society.
- 12 May 2020 According to a Catabasis Pharmaceuticals media release, data from an analysis of the baseline characteristics of patients enrolled in the Phase 3 PolarisDMD trial, age-normative growth and normal adrenal function seen in the Phase 2 MoveDMD trial presented at the 2020 Muscular Dystrophy Association (MDA) Virtual Poster Session.